Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immune tolerance induction: recombinant vs. human-derived product.

¹Department for Coagulation Disorders, Malmö University Hospital, Malmö, Sweden. erik.berntorp@medsforsk.mas.lu.se

Haemophilia : the Official Journal of the World Federation of Hemophilia

|January 3, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Fifth Åland Island conference on von Willebrand disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Replacement therapy during surgery in von Willebrand disease needs personalization.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Defining extended half-life rFVIII-A critical review of the evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Inducing immune tolerance (IT) is key for treating congenital haemophilia inhibitors. While both recombinant and human-derived factor VIII products can achieve IT, human-derived concentrates may offer better tolerizing effects.

Area of Science:

Hematology
Immunology
Pharmacology

Background:

High-responding inhibitors in congenital haemophilia pose a significant treatment challenge.
Immune tolerance (IT) induction is the primary therapeutic goal.
The impact of factor VIII product type on IT success is under investigation.

Purpose of the Study:

To explore the potential influence of factor VIII product type on immune tolerance induction in congenital haemophilia.
To compare the efficacy of recombinant versus human-derived factor VIII products in IT.

Main Methods:

Review of theoretical aspects and existing literature on factor VIII products and IT.
Analysis of factors potentially influencing tolerizing effects, such as product purity and von Willebrand factor content.

Related Experiment Videos

Main Results:

Immune tolerance induction is achievable with both recombinant and human-derived factor VIII products.
A lack of direct comparative studies exists.
Theoretical considerations suggest human-derived concentrates, particularly less purified ones with high von Willebrand factor content, may enhance tolerization.

Conclusions:

Both recombinant and human-derived factor VIII products can facilitate immune tolerance in haemophilia.
Further comparative studies are needed to definitively establish the superiority of any specific product type for IT induction.